Gyre Therapeutics (Gyre Therapeutics) Cash And Cash Equivalents : $33.5 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Cash And Cash Equivalents?

Gyre Therapeutics's quarterly cash and cash equivalents declined from Dec. 2021 ($26.09 Mil) to Dec. 2022 ($25.18 Mil) but then increased from Dec. 2022 ($25.18 Mil) to Dec. 2023 ($33.51 Mil).

Gyre Therapeutics's annual cash and cash equivalents declined from Dec. 2021 ($26.09 Mil) to Dec. 2022 ($25.18 Mil) but then increased from Dec. 2022 ($25.18 Mil) to Dec. 2023 ($33.51 Mil).

Gyre Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Gyre Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Cash And Cash Equivalents Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Cash And Cash Equivalents

26.09

25.18

33.51

Gyre Therapeutics Semi-Annual Data
	Dec21	Dec22	Dec23
Cash And Cash Equivalents	26.09	25.18	33.51

Gyre Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Gyre Therapeutics (NAS:GYRE) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Gyre Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023